Scopus BioPharma Retained Earnings (Accumulated Deficit) 2020-2023 | SCPS

Scopus BioPharma retained earnings (accumulated deficit) from 2020 to 2023. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Scopus BioPharma Retained Earnings (Accumulated Deficit) 2020-2023 | SCPS

Scopus BioPharma retained earnings (accumulated deficit) from 2020 to 2023. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$169.8B
Vertex Pharmaceuticals (VRTX)$121.4B
Gilead Sciences (GILD)$109.7B
Bristol Myers Squibb (BMY)$106.4B
Regeneron Pharmaceuticals (REGN)$102.2B
CSL (CSLLY)$92.8B
GSK (GSK)$79.1B
Alnylam Pharmaceuticals (ALNY)$36.5B
Argenex SE (ARGX)$33.1B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$26.7B
Illumina (ILMN)$23.3B
Moderna (MRNA)$21.2B
BeiGene (BGNE)$21.1B
Genmab (GMAB)$15.3B
Incyte (INCY)$14.2B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.9B
Sarepta Therapeutics (SRPT)$12.4B
Insmed (INSM)$12.2B
Vaxcyte (PCVX)$11.8B
Bio-Techne Corp (TECH)$11.2B
QIAGEN (QGEN)$9.5B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.6B
Revolution Medicines (RVMD)$8.4B
Legend Biotech (LEGN)$8.3B
Exelixis (EXEL)$8.2B
Viking Therapeutics (VKTX)$8.2B
Intra-Cellular Therapies (ITCI)$8.1B